it's a non binding vote-- meaning the Gov't can simply over rule if they feel the threat is worthy. and in this specific case, no way they would not exercise that right. Zika is scary stuff.
The article reeks of desperation. Permabear -- 1 trick pony -- spin negative articles to collude with short sellers. He laughs in the face of real progress being made in cancer treatments. Pathetic human being.
I agree with you. I simply posted this as there was talk on other threads as to him leaving PFE to take the job at XON. That was not the case. Who knows, he could have put his name out there to be replaced in the merger -- all the while knowing his time was limited as an opportunity at XON had presented itself. These types of hires take a lot of time, so not out of the question.
He was forced out of PFE in February, 2016 and was not currently employed. See press release below. Regardless, I think it's a good hire, but the fact is, he was out of a job.
Pfizer ($PFE) is shaking up its corporate structure again as it prepares to merge with Allergan ($AGN) and further lays the groundwork for a potential split in a few years. The structural rejig pushes out Geno Germano, who has been leading Pfizer's global innovative pharma business, and elevates one top Allergan manager, Bill Meury, to the combined company's commercial leadership team.
As expected, Allergan CEO Brent Saunders will head up commercial operations as president and COO after the $160 billion deal closes. An internal rejig will happen at the same time: Pfizer's vaccines and oncology drugs will combine with its global innovative products business, creating one big unit, and some Allergan businesses will hook up with consumer healthcare.
Albert Bourla will run the combined drugs and vaccines unit, leaving Germano, current head of global innovative pharma, out of a job. The established products business will remain, with current exec John Young at the helm and all of Hospira's commercial operations in his charge.
The SEC is useless. Just another bloated branch of government that is broken. It's no wonder why so many people have become disenchanted with investing in the markets.
Biased short sided articles based on opinion have driven the stock price down over 30%. Today's piece was from a freakin' "mailbag." What's next, retail investors sell because Dear Abby comes out and says Kirk kissed his cousin?? Grow a pair already and have some conviction in your investments!
i think we are finally closer to the end of the biotech decimation. some real values presenting themselves. the pendulum has swung too far negative. i think we see some substantial news for XON in the next few months that will put a long term bottom firmly in place.
going on for over a month now. until we see new institutional buyers stepping forward, this will continue to be a playground for shorts. the volume is anemic and price easily manipulated.
Kudos to the politicians in Grand Cayman, they obviously understand priorities lie with keeping their citizens safe from disease! Meanwhile, US congress is enjoying yet another break from doing absolutely nothing.
The lawsuits are based on a seeking alpha article NOT fact. The company pays Price Waterhouse over $1 million / year to audit the books. Do you really think they would miss revenue recognition figures knowing that ECCs are part of the XON business model?
It's all part of the short sellers master plan, create doubt & fear amongst the investor base. Timed perfectly might I add as XON is in a "quiet period" before the Q1 earnings announcement.
pitiful. at this rate a stellar earnings call next week and the stock will pop to $25. management really should be ashamed. stock has done nothing but go down for 9 months (since late july 2015) now.
Do people realize XON has zero debt and $135 million in cash on the balance sheet.? Not to mention a feasible path to $200 million in revenue in 2017 from established and growing revenue streams like Tans Ova?
These figures do not even value the intrinsic value of all the ECCs, Isobutanol, Oxitec, patents and future technologies currently being developed. The way folks talk about this stock being overvalued you think it was trading with a Market Cap of $30 billion not $3 billion. Comical really.
Take over control. Defend the company. Address the claims and debunk the SA research. Reassure the investing base that a medium / long term plan is intact. This stock has been in a free fall since July of 2015. WAKE THE F UP!